Vienna, Austria

Thomas Prenninger

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Baxalta Gmbh, Takeda Pharmaceutical Company Limited. Active years: 2019-2024.


% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Thomas Prenninger: Innovator in Particle Analysis

Introduction

Thomas Prenninger is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of particle analysis, holding a total of 2 patents. His work focuses on the characterization of subvisible particles, which is crucial in various scientific and industrial applications.

Latest Patents

Prenninger's latest patents include methods for characterizing a population of particles using a particle analyzer. These methods allow for the characterization of particles by size, absolute number, and their proteinaceous properties. This innovation enhances the understanding of particle behavior and properties, which is essential in many research and development processes.

Career Highlights

Throughout his career, Thomas Prenninger has worked with prominent companies such as Baxalta GmbH and Takeda Pharmaceutical Company Limited. His experience in these organizations has contributed to his expertise in the field of particle analysis and innovation.

Collaborations

Some of his notable coworkers include Christian Lubich and Birgit Maria Reipert. Their collaboration has likely fostered a productive environment for innovation and development in their respective fields.

Conclusion

Thomas Prenninger's contributions to particle analysis through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the scientific community and industry practices.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…